Vor Biopharma (VOR) Competitors $2.08 -0.10 (-4.36%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VOR vs. AUPH, CALT, PAHC, PRAX, MENS, SANA, RCUS, DYN, AMPH, and AVDLShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Aurinia Pharmaceuticals (AUPH), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Praxis Precision Medicines (PRAX), Jyong Biotech (MENS), Sana Biotechnology (SANA), Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors Aurinia Pharmaceuticals Calliditas Therapeutics AB (publ) Phibro Animal Health Praxis Precision Medicines Jyong Biotech Sana Biotechnology Arcus Biosciences Dyne Therapeutics Amphastar Pharmaceuticals Avadel Pharmaceuticals Vor Biopharma (NYSE:VOR) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Is VOR or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of 23.31% compared to Vor Biopharma's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Vor Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A Aurinia Pharmaceuticals 23.31%20.06%13.81% Do analysts recommend VOR or AUPH? Vor Biopharma currently has a consensus price target of $5.63, indicating a potential upside of 169.96%. Aurinia Pharmaceuticals has a consensus price target of $12.00, indicating a potential upside of 3.41%. Given Vor Biopharma's higher possible upside, research analysts plainly believe Vor Biopharma is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer VOR or AUPH? In the previous week, Aurinia Pharmaceuticals had 45 more articles in the media than Vor Biopharma. MarketBeat recorded 47 mentions for Aurinia Pharmaceuticals and 2 mentions for Vor Biopharma. Aurinia Pharmaceuticals' average media sentiment score of 0.96 beat Vor Biopharma's score of 0.44 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 15 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, VOR or AUPH? Vor Biopharma has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Which has higher earnings and valuation, VOR or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Vor Biopharma. Vor Biopharma is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$1.51-1.38Aurinia Pharmaceuticals$260.11M5.87$5.75M$0.4326.99 Do institutionals & insiders believe in VOR or AUPH? 97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 2.9% of Vor Biopharma shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAurinia Pharmaceuticals beats Vor Biopharma on 10 of the 14 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryMedical SectorNYSE ExchangeMarket Cap$265.31M$215.37M$5.46B$20.65BDividend YieldN/AN/A4.71%3.67%P/E Ratio-1.27N/A28.7529.25Price / SalesN/AN/A438.0462.21Price / CashN/AN/A35.6823.31Price / BookN/AN/A8.154.42Net IncomeN/AN/A$3.25B$995.90M7 Day Performance-5.66%-14.57%-0.97%-0.22%1 Month Performance10.61%-9.96%5.25%-0.75%1 Year Performance139.66%137.36%28.36%15.55% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma2.7767 of 5 stars$2.09-4.4%$5.63+170.0%+172.5%$265.31MN/A-1.27140AUPHAurinia Pharmaceuticals2.185 of 5 stars$8.89-0.4%$11.50+29.4%+117.9%$1.20B$247.30M31.75300Trending NewsEarnings ReportInsider TradeAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.2696 of 5 stars$28.92-0.9%$24.40-15.6%+53.9%$1.17B$1.19B37.081,940Positive NewsPRAXPraxis Precision Medicines1.7195 of 5 stars$55.65-6.0%$94.11+69.1%-10.7%$1.13B$8.55M-5.19110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMENSJyong BiotechN/A$14.48+4.9%N/AN/A$1.10BN/A0.0031SANASana Biotechnology3.442 of 5 stars$4.88-1.4%$9.17+87.8%-12.0%$1.10BN/A-5.55380News CoverageRCUSArcus Biosciences2.1572 of 5 stars$9.85-3.7%$21.29+116.1%-30.7%$1.08B$141M-2.35500DYNDyne Therapeutics3.6649 of 5 stars$9.31-6.4%$40.63+336.4%-74.6%$1.06BN/A-2.59100Upcoming EarningsAnalyst ForecastGap DownTrading HaltedAMPHAmphastar Pharmaceuticals4.3079 of 5 stars$22.24-0.6%$32.33+45.4%-46.9%$1.05B$730.66M8.062,028News CoveragePositive NewsAVDLAvadel Pharmaceuticals2.8232 of 5 stars$10.83-1.8%$18.33+69.3%-30.9%$1.05B$169.12M-40.1170 Related Companies and Tools Related Companies AUPH Competitors CALT Competitors PAHC Competitors PRAX Competitors MENS Competitors SANA Competitors RCUS Competitors DYN Competitors AMPH Competitors AVDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VOR) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
